NO20006194L - Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri - Google Patents

Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri

Info

Publication number
NO20006194L
NO20006194L NO20006194A NO20006194A NO20006194L NO 20006194 L NO20006194 L NO 20006194L NO 20006194 A NO20006194 A NO 20006194A NO 20006194 A NO20006194 A NO 20006194A NO 20006194 L NO20006194 L NO 20006194L
Authority
NO
Norway
Prior art keywords
treatment
bowel syndrome
irritable bowel
functional dyspepsia
pharmaceutical composition
Prior art date
Application number
NO20006194A
Other languages
English (en)
Other versions
NO327738B1 (no
NO20006194D0 (no
Inventor
Per Hellstroem
Suad Efendic
Original Assignee
Per Hellstroem
Suad Efendic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Per Hellstroem, Suad Efendic filed Critical Per Hellstroem
Publication of NO20006194D0 publication Critical patent/NO20006194D0/no
Publication of NO20006194L publication Critical patent/NO20006194L/no
Publication of NO327738B1 publication Critical patent/NO327738B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20006194A 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning NO327738B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (3)

Publication Number Publication Date
NO20006194D0 NO20006194D0 (no) 2000-12-06
NO20006194L true NO20006194L (no) 2001-01-25
NO327738B1 NO327738B1 (no) 2009-09-14

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006194A NO327738B1 (no) 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning

Country Status (19)

Country Link
US (1) US6348447B1 (no)
EP (2) EP1094834B1 (no)
JP (2) JP2002517468A (no)
AT (1) ATE252912T1 (no)
AU (1) AU738994B2 (no)
CA (1) CA2321700C (no)
CZ (1) CZ300873B6 (no)
DE (1) DE69912434T2 (no)
DK (1) DK1094834T3 (no)
ES (1) ES2205845T3 (no)
HU (1) HUP0103147A3 (no)
NO (1) NO327738B1 (no)
NZ (1) NZ506163A (no)
PL (1) PL198802B1 (no)
PT (1) PT1094834E (no)
RU (1) RU2226402C2 (no)
SE (1) SE9802080D0 (no)
WO (1) WO1999064060A1 (no)
ZA (1) ZA200004080B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK2280021T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising insulin complexed to a diketopiperazine
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CA2402733A1 (en) 2000-03-14 2001-09-20 Burkhard Goke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
ES2307619T3 (es) 2000-05-19 2008-12-01 Amylin Pharmaceuticals, Inc. Tratamiento del sindrome coronario agudo con glp-1.
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
EP2210612B1 (en) 2003-06-18 2016-10-05 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
DK2314298T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Microparticles comprising diketopiperazinsalte for drug delivery
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
EP1881850B1 (en) 2005-05-13 2010-09-29 Eli Lilly And Company Glp-1 pegylated compounds
EP1904525A4 (en) 2005-06-30 2009-10-21 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
ES2531159T3 (es) * 2005-07-29 2015-03-11 Solasia Pharma K K Compuestos y métodos para el tratamiento del cáncer
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1
WO2008134425A1 (en) * 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CN101969928B (zh) * 2007-10-24 2014-05-07 曼金德公司 活性剂的递送
AU2008316634B2 (en) * 2007-10-24 2014-02-27 Mannkind Corporation Method of preventing adverse effects by GLP-1
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
RU2543157C2 (ru) 2008-06-17 2015-02-27 Глитек,Инк. Гликозилированный пептид glp-1
DK2300083T3 (da) 2008-06-20 2013-07-22 Mannkind Corp Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011013728A1 (ja) * 2009-07-29 2011-02-03 第一三共株式会社 経粘膜吸収性を付与したモチリン類似ペプチド化合物
CA2778890A1 (en) 2009-10-30 2011-05-05 Otsuka Chemical Co., Ltd. Glycosylated form of antigenic glp-1 analogue
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
WO2011123943A1 (en) * 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
WO2014016300A1 (en) 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
DK3257524T3 (da) 2015-02-11 2020-11-23 Gmax Biopharm Llc Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
ES2960687T3 (es) 2018-02-02 2024-03-06 Novo Nordisk As Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CN110305211A (zh) 2018-03-20 2019-10-08 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
DK1094834T3 (da) 2004-01-05
DE69912434D1 (de) 2003-12-04
WO1999064060A1 (en) 1999-12-16
US6348447B1 (en) 2002-02-19
CZ300873B6 (cs) 2009-09-02
NZ506163A (en) 2004-10-29
SE9802080D0 (sv) 1998-06-11
CA2321700A1 (en) 1999-12-16
CZ20004491A3 (en) 2001-05-16
ES2205845T3 (es) 2004-05-01
AU738994B2 (en) 2001-10-04
NO327738B1 (no) 2009-09-14
PL343104A1 (en) 2001-07-30
JP2010270125A (ja) 2010-12-02
PL198802B1 (pl) 2008-07-31
JP2002517468A (ja) 2002-06-18
ZA200004080B (en) 2001-12-24
HUP0103147A3 (en) 2002-02-28
RU2226402C2 (ru) 2004-04-10
PT1094834E (pt) 2004-03-31
DE69912434T2 (de) 2004-05-06
CA2321700C (en) 2011-05-03
EP1094834A1 (en) 2001-05-02
NO20006194D0 (no) 2000-12-06
AU4669799A (en) 1999-12-30
EP1094834B1 (en) 2003-10-29
EP1405642A1 (en) 2004-04-07
HUP0103147A2 (hu) 2002-01-28
ATE252912T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
NO20006194D0 (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
NO984005L (no) Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
ATE316100T1 (de) Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
ATE193541T1 (de) Insulinotropes hormon
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
NO20041203L (no) Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
NO964548D0 (no) Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
DE69419527T2 (de) Laxiermittel das ballastfasern und dioctyl-sulfosuccinat enthält
NO972849L (no) Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
DE69011618D1 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
WO2003092619A3 (en) Prevention and treatment of type 2 diabetes
Kozarek The future of invasive pancreaticobiliary endoscopy
SE8501202D0 (sv) Human intestinal hormone and its use
PT1103270E (pt) Tratamento de doencas auto-imunes em mamiferos
SE8501203D0 (sv) Mammal intestinal hormone precursor and its use
IT9048106A0 (it) Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516)
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees